Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 7/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MAN2A1 | Q16706 | 1/20 | 0.38 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140788 | 1.00 | SSTR4 (0.44) | SSTR4CHRM2CHRM1CHRM3MAN2A1 | |
| SCHEMBL4878440 | 1.00 | SSTR4 (0.44) | SSTR4CHRM2CHRM1CHRM3MAN2A1 | |
| Hydrochloric Acid SCHEMBL4131155 | 0.99 | SSTR4 (0.43) | SSTR4CHRM2CHRM1CHRM3MAN2A1 | |
| Hydrochloric Acid SCHEMBL4131159 | 0.99 | SSTR4 (0.43) | SSTR4CHRM2CHRM1CHRM3MAN2A1 | |
| SCHEMBL4152926 | 0.88 | SSTR4 (0.42) | SSTR4CHRM2CHRM1CHRM3MAN2A1 | |
| SCHEMBL4487733 | 0.84 | CNR1 (0.49) | SSTR4CHRM2CHRM1CHRM3CNR1 | |
| SCHEMBL5106109 | 0.84 | CNR1 (0.49) | SSTR4CHRM2CHRM1CHRM3CNR1 | |
| SCHEMBL4136635 | 0.83 | SSTR4 (0.50) | SSTR4CHRM2CHRM1CHRM3CNR1 | |
| SCHEMBL4136638 | 0.83 | SSTR4 (0.50) | SSTR4CHRM2CHRM1CHRM3CNR1 | |
| SCHEMBL4617514 | 0.81 | HTR4 (0.41) | CHRM2CHRM1CHRM3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | claimed |
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| US-20070021487-A1 | Azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | ADRB2, ADRB1, ADRA2C | SSTR4 1022/4885CHRM2 9/4885CHRM1 27/4885 |
| US-20070021487-A1 | Azabicyclo derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | SSTR4 836/4885CHRM2 3/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.